FDA’s Guidance for 503A Compounding of COVID-19

by | Apr 24, 2020

Following our previous posts on FDA’s guidance released this week, Dr. David Hussong discusses the terms stipulated by the temporary policy which allows 503A pharmacies to compound certain drugs for COVID-19 without patient-specific prescriptions.

Thank you for reading this post, don't forget to subscribe!

Watch this episode of Eagle TV to hear more! Have a question for our experts? Visit our COVID-19 resource page and access our fact check form to get science-based answers from our team.

Subscribe to our YouTube Channel to get alerts when we post videos 


Eagle Analytical
Verified by MonsterInsights